文献速递血栓与止血

国产血源性凝血因子Ⅸ治疗血友病B患者安全性和有效性的Ⅲ期多中心临床试验

[A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

本研究为多中心、开放、单臂Ⅲ期试验,纳入36例血友病B患者,用目标值法评价国产血源性人凝血因子Ⅸ(pd-FⅨ)治疗急性出血的有效性和安全性。36次首次出血事件中止血效果优良27次(75.00%)、良好9次(25.00%),首次输注后30分钟中位回收率为111.92%(65.55%~194.28%)。未发生研究药物相关不良事件,未发生病毒感染,首次用药后90~104天FⅨ抑制物均为阴性。

要点

  • 36次急性出血事件中止血效果优良27次(75.00%)、良好9次(25.00%)。
  • 首次输注后30分钟FⅨ中位回收率为111.92%(65.55%~194.28%)。
  • 未发生研究药物相关不良事件,未发生病毒感染,FⅨ抑制物均为阴性。

核心结论

  • 试验所用国产血源性人凝血因子Ⅸ治疗血友病B具有良好的有效性及安全性。

研究设计与样本

  • 多中心、开放、单臂研究,采用目标值法评价国产血源性人凝血因子Ⅸ的有效性。
  • 共纳入36例血友病B受试者,中位年龄31岁,中位用药次数为4(1~17)次。
  • 根据出血状况和FⅨ水平确定输注剂量,首次输注后30分钟测定FⅨ回收率,(24±4)小时观察出血症状和体征改善。
  • 记录不良事件,首次输注后90天检测病原微生物指标及FⅨ抗体。

主要发现

  • 36次首次出血事件中,止血效果优良27次(75.00%),良好9次(25.00%)。
  • 首次输注结束后30分钟FⅨ中位回收率为111.92%(65.55%~194.28%)。
  • 未发生研究药物相关不良事件。
  • 未发生病毒感染。
  • 所有受试者首次用药后90~104天检测FⅨ抑制物均为阴性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of a domestic human plasma derived coagulation Factor Ⅸ concentrate (pd-FⅨ) in patients with hemophilia B. Methods: The study was a multicenter, open-label and single-arm study. The efficacy of pd-F Ⅸ was evaluated by objective performance criteria. The doses of pd-FⅨ were calculated according to the bleeding symptom and disease severity. The infusion efficiency of pd-FⅨ and improvement of bleeding symptoms were measured at 30 minutes and (24±4) h after the first infusion, respectively. Adverse events were recorded. Viral infection and FⅨ inhibitor were detected 90 d after the first infusion. Results: All 36 subjects with hemophilia B were enrolled in the study. The median age of these patients was 31 years old and the median injection doses were 4 (1-17) times. The hemostatic effect of 27/36 (75.00%) and 9/36 (25.00%) acute bleeding events were rated as "excellent" and "better" , respectively. The recovery rate was 111.92% (65.55%-194.28%) at 30 minutes after infusion of FⅨ. There was no adverse event related to FⅨ. No reactivation of HBV, HCV or HIV and FⅨ inhibitor was detected at 90-104 d after the first FⅨ infusion. Conclusion: This domestically made human plasma derived FⅨ concentrate is safe and effective in the treatment of acute bleeding in patients with hemophilia B. Clinical trial registration: China food and Durg Administration, 2016L08027. 目的: 评价一种国产血源性人凝血因子Ⅸ(FⅨ)治疗血友病B的有效性和安全性。 方法: 采用多中心、开放、自身对照设计,用目标值法评价FⅨ的有效性。根据入组血友病B受试者的出血状况和FⅨ水平确定输注剂量,首次输注后30 min测定FⅨ回收率,(24±4)h观察出血症状和体征改善,记录不良事件,治疗后90 d检测病原微生物指标及FⅨ抗体。 结果: 36例血友病B患者纳入研究,中位年龄31岁,中位用药次数为4(1~17)次。受试者入组后36次首次出血中,止血效果优良、良好分别为27次(75.00%)、9次(25.00%)。首次输注结束后30 min的FⅨ中位回收率为111.92%(65.55%~194.28)%。未发生研究药物相关不良事件。未发生病毒感染。所有受试者首次用药后90~104 d检测FⅨ抑制物均为阴性。 结论: 试验所用国产血源性FⅨ治疗血友病B具有良好的有效性及安全性。 临床试验注册: 国家食品药品监督管理总局2016L08027.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu W, Fu RF, Zhou YW, et al. [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29779350. doi:10.3760/cma.j.issn.0253-2727.2018.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。